The aim of this study was to examine the prevalence of activation cluster adverse events ( AC-AEs ) in youths treated with the selective serotonin reuptake inhibitor ( SSRI ) fluvoxamine for anxiety and the relationship of AC-AEs to SSRI blood levels .
